CTSC and malignant colon neoplasm: In conclusion, we have developed a gene expression score, based on ZNF697, CTSC, SNORA2B, and OXLD1, that effectively stratifies patients with stage II colon cancer into low and high‐risk groups, facilitating the identification of patients who may benefit from adjuvant chemotherapy.